COMP <GO>
HCA vs ABBV // ENTERPRISE SCALE & MARKET CAP
HCA Healthcare Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HCA 6
— ABBV 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $473.19 (-1.02%) • MKT CAP: $103.51B
market-cap
$103.51B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 29.00% | -10.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.5x | 33.3x | -21.80 | HCA | /valuation <GO> |
| Free Cash Flow Yield | 7.43% | 3.47% | +3.96 | HCA | /fcf-yield <GO> |
| Operating Margin | 10.90% | 24.60% | -13.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 6.90% | +2.10 | HCA | /net-margins <GO> |
| Revenue Growth (YoY) | 7.10% | 8.60% | -1.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 2.27% | -1.61 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.68 | 5.33 | -1.65 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | HCA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | HCA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.7 | 72.8 | -12.09 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 14.2x | 113.1x | -98.90 | HCA | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $103.51B | $513.86B | -$410.35B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCA REV | ABBV REV | HCA GROSS % | ABBV GROSS % | HCA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.60B | $61.16B | 44.0% | 70.2% | $7.69B | $17.82B |
| FY 2024 | $70.60B | $56.33B | 44.0% | 70.0% | $5.64B | $17.83B |
| FY 2023 | $64.97B | $54.32B | 44.0% | 44.0% | $6.51B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCA // BETA 1.04
ABBV // BETA 1.15